Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea flag South Korea · Delayed Price · Currency is KRW
118,000
-3,100 (-2.56%)
Last updated: Jun 8, 2026, 1:38 PM KST

Daewoong Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,592,1991,570,8911,422,6831,375,3291,280,0921,152,976
Other Revenue
-0--0-0-0-0
1,592,1991,570,8911,422,6831,375,3291,280,0921,152,976
Revenue Growth (YoY)
10.31%10.42%3.44%7.44%11.03%9.24%
Cost of Revenue
771,590748,359688,516688,221641,997609,227
Gross Profit
820,609822,532734,168687,108638,095543,749
Selling, General & Admin
438,235427,581397,216376,109366,091315,434
Research & Development
183,055180,315171,290171,573163,602127,269
Amortization of Goodwill & Intangibles
3,9573,9894,6761,9191,9632,072
Other Operating Expenses
5,3395,1164,4764,3824,2973,554
Operating Expenses
641,590627,024588,929565,990542,297455,020
Operating Income
179,019195,508145,238121,11895,79788,729
Interest Expense
-12,290-12,475-6,986-13,603-8,406-10,248
Interest & Investment Income
2,8002,5965,0943,0994,1352,569
Earnings From Equity Investments
39,90046,141-23,15329,977-374.54257.52
Currency Exchange Gain (Loss)
-2,685-10,0456,261-1,705-40.313,246
Other Non Operating Income (Expenses)
-8,767-10,811-25,331-13,423-43,639-69,962
EBT Excluding Unusual Items
197,977210,913101,123125,46247,47314,591
Gain (Loss) on Sale of Investments
17,666-4,506-28,614130.67-4,1718,308
Gain (Loss) on Sale of Assets
79.9679.96-465.97-1,221246.4-1,029
Asset Writedown
-14,654-14,654-15,492-2,372-5,219-2,109
Pretax Income
201,069191,83356,550121,99938,33019,761
Income Tax Expense
2,427-1,07633,2041,996-833.51-10,323
Earnings From Continuing Operations
198,642192,90923,347120,00339,16330,084
Minority Interest in Earnings
1,2202,9471,3881,7363,076-5,578
Net Income
199,862195,85624,735121,73942,24024,506
Net Income to Common
199,862195,85624,735121,73942,24024,506
Net Income Growth
419.33%691.83%-79.68%188.21%72.37%92.15%
Shares Outstanding (Basic)
121212111111
Shares Outstanding (Diluted)
121212111111
Shares Change (YoY)
-0.03%-0.71%3.21%0.59%3.21%
EPS (Basic)
17369.4017021.642149.6510655.613815.952226.87
EPS (Diluted)
17369.4017021.642149.6510655.613815.952226.87
EPS Growth
419.47%691.83%-79.83%179.24%71.36%86.18%
Free Cash Flow
-82,286-42,329-103,65326,67152,98810,906
Free Cash Flow Per Share
-7151.19-3678.75-9008.372334.474786.97991.08
Dividend Per Share
600.000600.000----
Gross Margin
51.54%52.36%51.60%49.96%49.85%47.16%
Operating Margin
11.24%12.45%10.21%8.81%7.48%7.70%
Profit Margin
12.55%12.47%1.74%8.85%3.30%2.13%
Free Cash Flow Margin
-5.17%-2.70%-7.29%1.94%4.14%0.95%
EBITDA
234,018246,580194,217164,915135,492129,613
EBITDA Margin
14.70%15.70%13.65%11.99%10.59%11.24%
D&A For EBITDA
54,99951,07248,97843,79739,69540,883
EBIT
179,019195,508145,238121,11895,79788,729
EBIT Margin
11.24%12.45%10.21%8.81%7.48%7.70%
Effective Tax Rate
1.21%-58.72%1.64%--
Advertising Expenses
-83,36673,83679,24580,58759,081